← Back to Search

Procedure

Liver Transplantation for Bile Duct Cancer (LT for iCCA Trial)

Phase 2
Recruiting
Led By Gonzalo Sapisochin, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group: 0 or 1 at all times prior to Liver Transplantation
Patient not eligible for liver resection due to poor liver function/portal hypertension
Must not have
Renal dysfunction with an estimated creatinine clearance of less than 50 ml/min
Uncontrolled infection(s)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate the effectiveness of liver transplant as a treatment for very early intrahepatic cholangiocarcinoma (iCCA) diagnosed in cirrhotic patients.

Who is the study for?
This trial is for patients with very early-stage intrahepatic cholangiocarcinoma (iCCA) who have cirrhosis and are not candidates for liver resection. They must be in good physical condition (ECOG 0 or 1), without cancer symptoms, no vascular or biliary involvement, no extra-hepatic disease, and CA 19.9 levels ≤100 ng/mL. Exclusions include significant cardiac disease, renal dysfunction, HIV infection, prior organ transplants or iCCA treatments.
What is being tested?
The study tests the effectiveness of deceased donor liver transplantation as a potential cure for 'very early' iCCA in cirrhotic patients ineligible for resection surgery. Participants may receive bridging therapies before transplant and will be monitored over five years to assess survival rates and disease recurrence.
What are the potential side effects?
Liver transplantation can lead to complications such as rejection of the new liver by the body's immune system, infections due to immunosuppressive drugs required after surgery, bleeding issues, bile duct complications like leaks or strictures, and possible recurrence of cancer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have always been fully active or restricted in physically strenuous activity only.
Select...
I cannot have liver surgery due to poor liver function or high blood pressure in the liver.
Select...
My bile duct cancer is very early stage and the tumor is 2 cm or smaller.
Select...
I do not have symptoms caused by my cancer.
Select...
I have liver cirrhosis.
Select...
My liver cancer was caught very early.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidneys are not working well, with a low creatinine clearance rate.
Select...
I do not have any infections that are not responding to treatment.
Select...
My tumor has grown larger than 3 cm or has spread outside the liver.
Select...
I have had a solid organ transplant.
Select...
I have been diagnosed with HIV.
Select...
My current tumor is a recurrence after having liver surgery for cancer.
Select...
I have trouble breathing or lung problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Liver

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Liver transplantationExperimental Treatment1 Intervention
The intervention will consist of liver transplantation

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,524 Previous Clinical Trials
503,174 Total Patients Enrolled
3 Trials studying Liver Cancer
51 Patients Enrolled for Liver Cancer
Gonzalo Sapisochin, MDPrincipal InvestigatorUniversity Health Network, Toronto
5 Previous Clinical Trials
198 Total Patients Enrolled
Jordi Bruix, MDPrincipal InvestigatorHospital Clinic of Barcelona
3 Previous Clinical Trials
130 Total Patients Enrolled

Media Library

Deceased donor Liver Transplantation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT02878473 — Phase 2
Liver Cancer Research Study Groups: Liver transplantation
Liver Cancer Clinical Trial 2023: Deceased donor Liver Transplantation Highlights & Side Effects. Trial Name: NCT02878473 — Phase 2
Deceased donor Liver Transplantation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02878473 — Phase 2
~4 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top